Trial · NCT03214952
Adverse events18
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 18 of 18
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nausea | Gastrointestinal disorders | Vonoprazan 20 mg | 3 | 3,125 | |
| other | Rash | Skin and subcutaneous tissue disorders | Vonoprazan 20 mg | 4 | 3,125 | |
| other | Urticaria | Skin and subcutaneous tissue disorders | Vonoprazan 20 mg | 3 | 3,125 | |
| serious | Colon cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Vonoprazan 20 mg | 2 | 3,125 | |
| serious | Gastric cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Vonoprazan 20 mg | 4 | 3,125 | |
| serious | Lymphoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Vonoprazan 20 mg | 1 | 3,125 | |
| serious | Oesophageal carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Vonoprazan 20 mg | 1 | 3,125 | |
| serious | Pancreatic carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Vonoprazan 20 mg | 1 | 3,125 | |
| serious | Rectal cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Vonoprazan 20 mg | 1 | 3,125 | |
| serious | Lung neoplasm malignant | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Vonoprazan 20 mg | 2 | 3,125 | |
| serious | Alcoholic psychosis | Psychiatric disorders | Vonoprazan 20 mg | 1 | 3,125 | |
| serious | Cerebral infarction | Nervous system disorders | Vonoprazan 20 mg | 1 | 3,125 | |
| serious | Aortic aneurysm rupture | Vascular disorders | Vonoprazan 20 mg | 1 | 3,125 | |
| serious | Diarrhoea | Gastrointestinal disorders | Vonoprazan 20 mg | 1 | 3,125 | |
| serious | Duodenal ulcer haemorrhage | Gastrointestinal disorders | Vonoprazan 20 mg | 1 | 3,125 | |
| serious | Hepatic function abnormal | Hepatobiliary disorders | Vonoprazan 20 mg | 1 | 3,125 | |
| serious | Arthritis | Musculoskeletal and connective tissue disorders | Vonoprazan 20 mg | 1 | 3,125 | |
| serious | Pyrexia | General disorders | Vonoprazan 20 mg | 1 | 3,125 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03214952/events